DexCom, Inc. (VIE:DXCM)
Austria · Delayed Price · Currency is EUR | Market Cap | 26.84B +12.8% |
| Revenue (ttm) | 4.35B +15.5% |
| Net Income | 875.04M +74.9% |
| EPS | 2.27 +77.4% |
| Shares Out | n/a |
| PE Ratio | 31.42 |
| Forward PE | 27.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 71.80 |
| Previous Close | 70.80 |
| Day's Range | 71.40 - 72.20 |
| 52-Week Range | 47.32 - 79.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;... [Read more]
Financial Performance
In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.
Financial numbers in USD Financial StatementsNews
DexCom announces $1B share repurchase program
On October 29, Dexcom (DXCM) announced that its Board of Directors authorized and approved a share repurchase program of up to $1B of Dexcom’s outstanding common stock, with a repurchase…
DexCom narrows FY26 revenue view to $5.20B-$5.25B, consensus $5.23B.
Prior guidance was $5.15B-$5.25B. Sees FY26: Non-GAAP Gross Profit Margin of approximately 64%, Non-GAAP Operating Margin of approximately 24%.
DexCom reports Q3 EPS 73c, consensus 67c
Reports Q3 revenue $1.34B, consensus $1.33B.U.S. revenue grew 14% and international revenue grew 5% on a reported basis and 5% on an organic1 basis, all on a year-over-year basis. “This…
DexCom Earnings Call Transcript: Q3 2026
Q3 revenue rose 11% with U.S. share gains and expanded margins; FY revenue and profitability guidance increased. Broader CGM access, product launches, and manufacturing scale-up underpin growth, while payer changes and Ireland ramp costs remain watchpoints.
DexCom Earnings release: Q3 2026
DexCom released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
DexCom Slides: Q3 2026
DexCom has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
DexCom Quarterly report: Q3 2026
DexCom has published its Q3 2026 quarterly earnings report on October 29, 2026.
Dexcom Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.
DexCom announces Dexcom G7 15 Day CGM to launch in Canada
DexCom (DXCM) announced that the Dexcom G7 15 Day Continuous Glucose Monitoring System, CGM, will be available in Canada beginning next month for adults 18 years and older living with…
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) w...
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pil...
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
DexCom shares jump 2.4% premarket after study results published in NEJM
DexCom (DXCM) on Wednesday announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine, providing rigorous evidence of the s...
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published...
DexCom price target raised to $100 from $95 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom (DXCM) to $100 from $95 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
DexCom price target raised to $96 from $90 at BTIG
BTIG raised the firm’s price target on DexCom (DXCM) to $96 from $90 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management wi...
DexCom initiated with an Overweight at Barclays
Barclays initiated coverage of DexCom (DXCM) with an Overweight rating and $115 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
DexCom announces launch of fifth season of Dexcom U
DEXCOM (DXCM) announced the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL program exclusively for college athletes with diabetes. Now in its fifth year, this marks…
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Ima...
DexCom price target raised to $105 from $90 at RBC Capital
RBC Capital raised the firm’s price target on DexCom (DXCM) to $105 from $90 and keeps an Outperform rating on the shares as part of a broader research note previewing…
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in ...
DexCom price target raised to $102 from $93 at Truist
Truist raised the firm’s price target on DexCom (DXCM) to $102 from $93 and keeps a Buy rating on the shares. The management continues to sound confident in a CMS…